Archive for the 'Pharmacoeconomic analysis' Category

10 Oct

Models for pharmacoeconomic analysis: COMPARISON OF MODELS

Different models often necessitate different comparisons of drugs, outcomes of therapy or both. As well, there may be different measures considered within similar models. As a result, direct comparisons between studies may not be feasible. Similarly, aggregation of data using meta-analytic techniques may not be possible. In general, prospective studies focus on short term, acute […]

09 Oct

Models for pharmacoeconomic analysis: PHARMACOECONOMIC EVALUATION MODELS(4)

Predictive models Predictive models are often referred to as decision tree analyses because they usually involve the construction and use of decision trees to model the clinical management and outcomes found in the ‘average’ clinical practice. Figure 1 depicts an example of a predictive model. An example was presented by Arikian and colleagues. buy prednisone

08 Oct

Models for pharmacoeconomic analysis: PHARMACOECONOMIC EVALUATION MODELS(3)

Retrospective models Retrospective models involve collection and comparison of data through review of patient charts or databases. In this model, outcomes and costs are known or have been recorded so the analysis is planned (a priori) before collecting the appropriate data. As an example, Meltzer et al performed a retrospective analysis comparing clozapine with standard […]

07 Oct

Models for pharmacoeconomic analysis: PHARMACOECONOMIC EVALUATION MODELS(2)

Prospective models The prospective model is associated with a clinical trial comparing drugs or treatments. This type of model offers a direct comparison between two or more treatments and can be performed with reasonable ease during phase III trials. A great advantage is the ability to capture costs and determine outcomes as they arise, rather […]

06 Oct

Models for pharmacoeconomic analysis: PHARMACOECONOMIC EVALUATION MODELS(1) / generic vardenafil online

As stated above, pharmacoeconomic models incorporate patient outcomes to provide a complete picture of therapy comparisons. These evaluations reflect real world practice over time and are therefore the preferred approach for drug comparisons. For an analysis to be termed ‘pharmacoeconomic’ three requirements must be met. First, there must be a comparison between at least two […]

05 Oct

Models for pharmacoeconomic analysis: MODELS OF COST ANALYSIS FOR DRUGS

A simplistic view of cost evaluation is the cost of drug model which merely compares the acquisition cost of two drugs, declaring the lower-priced choice to be the best value. If the two drugs are identical in all respects, such as a brand name drug and the generic copy produced by the same company, then […]

04 Oct

Models for pharmacoeconomic analysis: COST ANALYSIS VERSUS PHARMACOECONOMIC ANALYSIS

Cost analyses consider only the costs of inputs into care. These cost identification models include cost of drug comparisons and cost of regimen analysis. Table 1 describes their essential elements. Nondrug applications include burden of illness studies, cost of service analysis and cost justification. It’s time to pay less money – just get buy Tavist […]

Pages: 1 2 Next

© 2008 HIV/AIDS News & Information